SELLAS Life Sciences Group, Inc. - SLS Company Short-Term Debt

SELLAS Life Sciences Group (SLS) - corporate logo

SELLAS Life Sciences minimizes biopharmaceutical risks by developing immunotherapy to prevent tumor recurrence. The business focuses on combating aggressive leukemia, occupying a specific oncology segment. The current metric is 0.00. Stability is provided by vaccine development in the final stages of R&D and patent protection against generics. This price chart below clearly demonstrates the financial parameters of this asset.

Company Short-Term Loans and Borrowings: SELLAS Life Sciences Group Inc. (SLS) for 07/04/2022 - 10/28/2026

SELLAS Life Sciences Group, Inc. - analytical breakdowns and key metrics (SLS)

- price and consensus price forecast:
Stock Price SELLAS Life Sciences Group Inc.|SLS - Average Forecast Price
- market capitalization data:
Market Value SELLAS Life Sciences Group|SLS - Value Adjusted for Debt and Cash
- book capitalization data:
Accounting Value per Share SELLAS Life Sciences|SLS - Accounting Value of Company|Market Capitalization to Book Value Ratio sellaslifesciences.com|SLS - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio SELLAS Life Sciences|SLS - Long-Term Debt to Capital|Short-Term Debt to Equity SELLAS Life Sciences Group Inc.|SLS - Aggregate Debt Obligations|Debts to Book Capitalization SELLAS Life Sciences Group|SLS - Long-Term Debt|Company Short-Term Debt SELLAS Life Sciences
Analysis of all company metrics:sellaslifesciences.com, SLS
Manufactured products of SELLAS Life Sciences Group Inc.

For SELLAS Life Sciences (SLS), which is developing a leukemia vaccine, short-term borrowings under one year reflect current liquidity. This metric aggregates all obligations with a maturity of less than twelve months. The trend of this indicator measures the company's ability to fund clinical phases without emergency capital raises. An upward curve signals an increasing debt load, while a decline indicates the optimization of liabilities. This is a key solvency indicator prior to the company's commercial market entry.

Competitor analysis for SELLAS Life Sciences

ONC (BeiGene) - Company Short-Term Debts|HALO: Short-Term Debt|Company Short-Term Debt RevMed RVMD|Company Short-Term Loans and Borrowings Ascentage Pharma Corp|CGON - Company Current Liabilities|Company Short-Term Loans and Borrowings urogen.com|Company Short-Term Debts BCAX (Bicara Therapeutics)|Company Current Liabilities Personalis Inc PSNL|Company Current Liabilities ERAS (Erasca Corp)|Delcath Corp - Company Short-Term Debts|Company Short-Term Debt Y-mAbs Therapeutics (YMAB)|AURA - Company Short-Term Loans and Borrowings|Company Short-Term Debts CADL|ARAY (Accuray Inc) - Short-Term Debt|ACTU: Company Short-Term Debt|Short-Term Debt Volume Citius Oncology Inc|TuHURA Biosciences, Inc. - Company Short-Term Debts|Short-Term Debt TARA (protaratx.com)|Company Short-Term Debt Fate Therapeutics FATE|Aadi Bioscience, Inc. - Company Short-Term Debt|TCRX - Company Short-Term Debt|CSBR - Company Short-Term Debt|XBIT: Company Short-Term Debts|CVM (CEL-SCI) - Company Short-Term Debts|OSTX: Company Short-Term Debt|Short-Term Debt Volume Radiopharm Theranostics Ltd (RADX)|Artiva Biotherapeutics, Inc. (ARTV) - Company Current Liabilities|Company Short-Term Loans and Borrowings ANL (adlainortye.com)|Company Short-Term Debt Veru Inc. VERU|Company Short-Term Debt tempesttx.com TPST|Company Short-Term Debts XLO (Xilio)|RENB - Short-Term Debt Volume|Company Short-Term Debts muraloncology.com (MURA)|Kairos Pharma (KAPA) - Current Liabilities|Company Short-Term Debts OKUR (OnKure Therapeutics, Inc.)|Short-Term Debt CytoMed (GDTC)|Curis, Inc. (CRIS) - Company Current Liabilities|Company Short-Term Loans and Borrowings APLM (apollomicsinc.com)|Company Short-Term Debt THAR|Short-Term Debt Volume Advanced Biomed Inc. ADVB|GNPX: Company Short-Term Debts|CLDI - Company Current Liabilities|Sunshine Biopharma - Company Short-Term Debts|Xenetic Biosciences, Inc. (XBIO) - Short-Term Debt Volume|Company Short-Term Debts SLRX (Salarius)|Short-Term Debt PPBT|Company Short-Term Debt American Oncology Network AONC|Company Short-Term Indebtedness beigene.com (BGNE)|Checkpoint Therapeutics, Inc. - Company Short-Term Debts|Company Current Liabilities Elevation Oncology Inc. ELEV|ICAD (iCAD Corp) - Company Short-Term Debts|IKNA: Short-Term Debt|Notable Labs, Ltd. - Company Short-Term Debt|VIRX (Viracta Therapeutics, Inc.) - Short-Term Debt Volume|MOR: Company Short-Term Debt|Short-Term Debt Volume NAYA|Company Short-Term Debt Ascentage Pharma Group Ltd (AAPGV)